Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ESMO 21st World Congress on Gastrointestinal Cancer /
Applied precision cancer medicine in advanced biliary tract cancer

3rd - 7th Jul 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 15.07.19
Views: 263

Dr Hossein Taghizadeh - Medical University of Vienna, Vienna, Austria

Dr Hossein Taghizadeh speaks to ecancer at ESMO 21st World Congress on Gastrointestinal Cancer about applied precision cancer medicine in advanced therapy-refractory biliary tract cancers (BTC).

He explains that they used real-world data to detect possible targetable genomic mutations that may be used for tailored and targeted therapy.

Dr Taghizadeh concludes that the study showed that precision cancer medicine has the potential for being used to determine treatment options for patients with BTC.

 

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation